Summary
Other Scenarios:
- RHHBY - DNA
- RHHBY - AMGN
- DNA - SHR
- AMGN - SHR
| Buyer: | Roche Holding Ltd. (ADR) (RHHBY) | Last Price: | 91.15 | Market Cap.: | 157.25B |
|---|---|---|---|---|---|
| Target: | Schering AG (ADR) (SHR) | Last Price: | 120.31 | Market Cap.: | 22.96B |
Lines of Business Summary:
- Roche Holding Ltd. (ADR) (RHHBY) competes in 1 industry and 178 product/service groups
- Schering AG (ADR) (SHR) competes in 1 industry and 68 product/service groups
- A combined entity will have 2% Product/Service Group overlap
- Roche Holding Ltd. (ADR) (RHHBY) has 4 and Schering AG (ADR) (SHR) has 1 suppliers that rely on a material % of their business. They share 0 in common.
Product Summary:
Overlap & Complementary Sectors
| Sector | Buyer | Target | # of Focused Companies |
|---|---|---|---|
*Healthcare |
|
|
870 |
Biopharmaceuticals |
|
|
329 |
|
Medical Devices |
|
|
247 |
|
Scientific Products |
|
40 |
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Sample Products in Similar Lines of Business |
Sample Products in Complementary Lines of Business |
||
Buyer (Total: 231)
|
Target (Total: 79)
|
Buyer
|
Target
|
Business Relationship Summary:
Top Key Suppliers |
Top Key Customers |
||
Buyer (Total: 42)
|
Target (Total: 15)
|
Buyer (Total: 13)
|
Target (Total: 5)
|
Key Financial Summary:
Key Metrics
| Buyer | Target | |
|---|---|---|
| Number of Employees | 68,218 | 23,098 |
| Revenue Per Employee | 479,624.4 | 308,724.3 |
| Total Revenue | 15,661.8 | 1,779.7 |
| Total Expenses | 11,081.4 | 1,566.3 |
Other Revenue
|
0.0 | 0.0 |
|
Cost of Revenue
|
3,893.2 | 415.4 |
|
SG&A Expense
|
4,955.2 | 738.0 |
|
Research & Development
|
2,416.9 | 310.0 |
|
Other Operating Expense
|
-573.6 | 102.9 |
|
Operating Income
|
4,580.4 | 213.4 |
|
Unusual Income
|
0.0 | 0.0 |
|
LT Debt to Capital
|
18.78 | 5.88 |
|
Fwd P/E
|
24.82 | n/a |
|
Fwd P/Rev
|
n/a | n/a |
| Book Value | 27,367.3 | 4,297.3 |
|
Curr Portion of LTD/Cap Lease
|
271.4 | 30.1 |
Individual Company Summary
Focused
Buyer
Focused ():
*Healthcare > Biopharmaceuticals
Target
Focused ():
*Healthcare > Biopharmaceuticals
Business Description
Buyer
Roche Holding Ltd. is in the business of pharmaceuticals and diagnostics. Its pharmaceutical division offers a portfolio of medicines in various therapeutic areas, including cancer, human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS), hepatitis C, transplantation, dermatology and influenza. The Company's diagnostic division supplies an array of testing products and services to researchers, physicians, patients, hospitals and laboratories worldwide. Its products and services address prevention, diagnosis, treatment and the monitoring of diseases. The Company has operations in approximately 150 countries. During the year ended December 31, 2004, the Company has 64 new molecular entities in the research and development pipeline. In 2004, the Company's first deoxyribonucleic acid (DNA) chip-based test introduced to support more personalized therapy.
Target
Schering AG is a global research-based company engaged in the discovery, development, manufacture, marketing and sale of pharmaceutical products. The Company operates eight research and development centers in Europe, the United States and Japan, produce products in facilities located in Europe, the United States, Latin America and Asia, and markets and sells its products in over 100 countries worldwide. Its research and development efforts are primarily concentrated on the commercialization of technologies for unmet medical needs in its four core business areas: Gynecology & Andrology, Diagnostic Imaging, Specialized Therapeutics and Oncology. The Company derived approximately 38% of its net sales, during the year ended December 31, 2005, from sales of four key products: Betaferon, sold in the United States and Canada under the Betaseron trademark (16% of net sales); Yasmin (11%); Magnevist (6%), and Ultravist (5%). Bayer AG gained control of a total of 88% of the Company in June 2006.
Deal Summary
Key Ratios
| Buyer | Target | |
|---|---|---|
|
Gross Margin %
|
73.8 | 76.83 |
|
Operating Margin %
|
24.41 | 15.61 |
|
Quick Ratio
|
3.01 | 1.76 |
|
Current Ratio
|
3.75 | 2.31 |
|
Coverage Ratio
|
0.03 | 0.02 |
| Total Assets | 54,020.5 | 7,378.4 |
| Return on Equity % | 19.31 | 17.64 |
| Return on Assets % | 9.72 | 10.27 |
|
Cash+ ST Inv. Per Share
|
9.46 | 8 |
| Total Debt | 7,530.9 | 298.7 |
| Total Debt to Equity % | 27.69 | 6.95 |
| Total Debt to Tangible Equity % | 42.91 | 8.61 |
|
Debt to Asset %
|
13.94 | 4.05 |
Product Summary
| Sector | Buyer | Target |
|---|---|---|
|
*Healthcare |
|
|
Biopharmaceuticals |
|
|
|
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
|
|
|
|
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
|
|
|
|
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
|
|
|
|
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
|
|
|
|
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
|
|
|
|
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
|
|
|
|
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
|
|
|
|
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
|
|
|
|
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
|
|
|
|
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
|
|
|
|
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes therapeutics that treat female genital disorders, pregnancy, and childbirth.
|
|
|
|
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
|
|
|
|
Ophthalmology
The Ophthalmology Subsector includes therapeutics that treat eye disorders, infections, inflammations and irritations.
|
|
|
|
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
|
|
|
|
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
|
|
|
|
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
|
|
|
|
Toxicology
The Toxicology Subsector includes therapeutics that treat harmful effects from exposure to toxic substances; narcotics, nicotine and alcohol withdrawal therapeutics are also included in this sector.
|
|
|
|
Transplantation
The Transplantation Subsectors includes therapeutics that treat rejection and infection associated with tissue transplantation into the human body.
|
|
|
|
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
|
|
|
|
Weight Management
The Weight Management Subsectors includes herapeutics that treat and manage weight disorders.
|
|
|
|
Wound Management
The Wound Management Subsector includes therapeutics that treat cuts, abrasions, and burns from trauma or diseases.
|
|
|
|
Medical Devices |
|
|
|
Cardiology
The Cardiology Subsector includes medical devices that diagnose, monitor, and treat diseases affecting the heart and proximal blood vessels. Common devices include vital sign monitors, cardiac defibrillators, pacemakers, and other surgical equipment.
|
|
|
|
Clinical Diagnostics
The Clinical Diagnostics Subsector includes medical devices that analyze human body specimens within a medical setting. These devices, including equipment, biological and chemical reagents are primarily used for the diagnosis of diseases.
|
|
|
|
Neurology
The Neurology Subsector includes medical devices that diagnose, monitor and treat neurological disorders.
|
|
|
|
Oncology
The Oncology Subsector includes medical devices that detect and treat cancers.
|
|
|
|
Radiology
The Radiology Subsector includes medical devices that generate images of internal physiology.
|
|
|
|
Urology
The Urology Subsector includes medical that diagnose and treat urinary tract and male reproductive disorders.
|
|
|
|
Vascular
The Vascular Subsector includes medical devices that diagnose and treat of conditions affecting the blood vessels.
|
|
|
|
Scientific Products |
|
|
|
Analytical Instruments
The Analytical Instruments Subsector includes scientific products that determine the quantitative and qualitative nature of biochemical samples.
|
|
|
|
Bioanalytical Instruments
The Bioanalytical Instruments Subsector includes scientific products, devices and apparatuses that determine the quantitative and qualitative nature of a biological samples.
|
|
|
|
Consumables
The Consumables Subsector includes chemicals, reagents, standards, media, and disposable labware that are normally depleted or worn out by continuous use.
|
|
|
|
General Laboratory Equipment
The General Laboratory Equipment Subsector includes products that are used during routine laboratory procedures, such as sample preparation, processing, storage, cleaning, and purification.
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Product Details
| Sector | Buyer | Target |
|---|---|---|
|
*Healthcare |
|
|
|
Biopharmaceuticals |
|
|
Allergies |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for treatment of allergic reactions in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of allergic reactions in very early stages of research where no human subject is involved.
Target Products:
|
|
|
Upper Respiratory |
|
|
|
Monoclonal Antibodies
Therapeutics that treat allergic reactions by specifically binding and inhibiting inflammatory substances.
Buyer Products:
|
|
|
|
Cardiovascular System |
|
|
|
Heart Disorders |
|
|
|
Angina |
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat chest pains by preventing the entry of calcium into heart muscle cells.
Buyer Products:
|
|
|
|
Arrhythmia |
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat abnormal rhythm of the heart beat by inhibiting the stimulation of beta adrenergic receptors of the heart muscle.
Target Products:
|
|
|
|
Heart Failure (HF) |
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat the ineffective pumping of the heart by blocking beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Loop Diuretic Agents
Therapeutics that treat the excessive accumulation of fluids by increasing the excretion of sodium, potassium, chloride ions, and water in urine.
Buyer Products:
|
|
|
|
Myocardial Infarction (MI) |
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat irreversible damage to the heart muscle by blocking the beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in very early stages of research where no human subject is involved.
Target Products:
|
|
|
|
Vascular Disorders |
|
|
|
Deep Vein Thrombosis (DVT) |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Platelet Aggregation Inhibitors |
|
|
|
Adenosine Diphosphate (ADP) Inhibitors
Therapeutics that treat/prevent thrombosis by selectively inhibiting the binding of adenosine diphosphate (ADP) to its platelet receptor, thereby inhibiting platelet aggregation.
Buyer Products:
|
|
|
|
Hypertension |
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
|
Loop Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of sodium, potassium, chloride ions, and water in urine.
Buyer Products:
|
|
|
|
Stroke |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Platelet Aggregation Inhibitors |
|
|
|
Adenosine Diphosphate (ADP) Inhibitors
Therapeutics that prevent or treat damage to nerve cells of the brain by preventing platelets from clumping together.
Buyer Products:
|
|
|
|
Thromboembolism |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.
Target Products:
|
|
|
|
Dermatology |
|
|
|
Acne |
|
|
|
Rosacea |
|
|
|
Azelaic Acid
Therapeutics that treat and prevent rosacea caused by bacteria.
Target Products:
|
|
|
|
Vulgaris |
|
|
|
Retinoids/Vitamin A Analogs
Therapeutics that treat acne by helping in cell differentiation as well as prevent cell proliferation.
Buyer Products:
|
|
|
|
Lesion/Scaling Disorders |
|
|
|
Psoriasis |
|
|
|
Monoclonal Antibodies
Therapeutics that treat psoriasis by binding to certain receptors on antigens associated with the disease, thus modulating the immune reaction.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skin disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Digestive System |
|
|
|
Gastrointestinal Tract Disorders |
|
|
|
Gastroesophageal Disorders |
|
|
|
Nausea/Vomiting |
|
|
|
Serotonin Receptor Antagonists
Therapeutics that treat nausea and vomiting by blocking the serotonin receptors.
Buyer Products:
|
|
|
|
Intestinal Disorders |
|
|
|
Inflammatory Bowel Disease (IBD) |
|
|
|
Crohn`s Disease |
|
|
|
Colony Stimulating Factors (CSF) |
|
|
|
Granulocyte Macrophage (rhGM-CSF)
Therapeutics that treat Crohn's Disease by inducing the maturation and proliferation of granulocytes, macrophages and mixed granulocyte-macrophage colonies of cells.
Target Products:
|
|
|
|
Stomatognathic Disorders |
|
|
|
Mucositis |
|
|
|
Colony Stimulating Factors (CSF) |
|
|
|
Granulocyte Macrophage (rhGM-CSF)
Therapeutics that treat mucositis by inducing the maturation and proliferation of granulocytes, macrophages and mixed granulocyte-macrophage colonies of cells.
Target Products:
|
|
|
|
Liver Disorders |
|
|
|
Cirrhosis |
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Loop Diuretic Agents
Therapeutics that prevent edema by excretion of sodium, potassium, chloride ions, and water in urine.
Buyer Products:
|
|
|
|
Hepatitis |
|
|
|
Hepatitis B |
|
|
|
Chronic |
|
|
|
Interferons
Therapeutics that treat hepatitis by providing a naturally occurring protein that stimulates the immune system.
Buyer Products:
|
|
|
|
Hepatitis C |
|
|
|
Chronic |
|
|
|
Interferons
Therapeutics that treat hepatitis by providing a naturally occurring protein that stimulates the immune system.
Buyer Products:
|
|
|
|
Interferons/Nucleoside Analogs
Therapeutics that treat viral infections by preventing viral replication, stimulating the immune system to also fight the virus, and inhibits replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Endocrinology/Metabolism |
|
|
|
Diabetes |
|
|
|
Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes |
|
|
|
Peroxisome Proliferator-Activated Receptor Agonists (PPAR Agonists)
Products that sensitizes organs to insulin.
Buyer Products:
|
|
|
|
Intermediary Metabolism Disorders |
|
|
|
Gout |
|
|
|
Gouty Arthritis |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that counteract or suppress inflammation preventing cyclooxygenase activity.
Buyer Products:
|
|
|
|
Parathyroid Gland Disorders |
|
|
|
Hyperparathyroidism (HPT) |
|
|
|
Vitamin D Analogs
Therapeutics that act similar to Vitamin D.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Reproductive Disorders |
|
|
|
Hypoestrogenism |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
Therapeutics that are female sex hormones.
Target Products:
|
|
|
|
Hypogonadism |
|
|
|
Female |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
Therapeutics that are female sex hormones.
Target Products:
|
|
|
|
Menopause |
|
|
|
Estrogens
Therapeutics that are female sex hormones.
Target Products:
|
|
|
|
Estrogens/Progestins
Therapeutics that are mixture of two female sex hormones that are important for the development of the female reproductive system.
Target Products:
|
|
|
|
Progestins
Therapeutics that are female sex hormones.
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Hematology |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Red Blood Cell (RBC) Disorders |
|
|
|
Anemia |
|
|
|
Recombinant Human Erythropoietins
Therapeutics that treat conditions characterized by reduced delivery of oxygen to body tissues by stimulating red blood cell production.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Serum Factor Disorders |
|
|
|
Hypocalcemia |
|
|
|
Vitamin D Analogs
Therapeutics that treat hypocalcemia by increasing serum levels of calcium, as well as helping the bone calcification process.
Buyer Products:
|
|
|
|
White Blood Cell (WBC) Disorders |
|
|
|
Neutropenia |
|
|
|
Colony Stimulating Factors (CSF) |
|
|
|
Granulocyte Macrophage (rhGM-CSF)
Therapeutics that treat neutropenia by inducing the maturation and proliferation of granulocytes, macrophages and mixed granulocyte-macrophage colonies of cells.
Target Products:
|
|
|
|
Immunology |
|
|
|
Autoimmune Disorders |
|
|
|
Arthritis |
|
|
|
Rheumatoid Arthritis (RA) |
|
|
|
Immunotherapy |
|
|
|
Monoclonal Antibodies
Therapeutics that treat rheumatoid arthritis by interfering with specific immune pathways implicated in the progression of the disease.
Buyer Products:
|
|
|
|
Inflammatory Bowel Disease (IBD) |
|
|
|
Crohn`s Disease |
|
|
|
Colony Stimulating Factors (CSF) |
|
|
|
Granulocyte Macrophage (rhGM-CSF)
Therapeutics that treat Crohn's Disease by inducing the maturation and proliferation of granulocytes, macrophages and mixed granulocyte-macrophage colonies of cells.
Target Products:
|
|
|
|
Multiple Sclerosis (MS) |
|
|
|
Interferons
Therapeutics that treat multiple sclerosis with a recombinant human protein that downregulates the antibody response of the immune system.
Target Products:
|
|
|
|
Psoriasis |
|
|
|
Monoclonal Antibodies
Therapeutics that treat psoriasis by binding to certain receptors on antigens associated with the disease, thus modulating the immune reaction.
Buyer Products:
|
|
|
|
Immune Deficiency Disorders |
|
|
|
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) |
|
|
|
Fusion Inhibitors
Therapeutics that manage HIV by inhibiting the fusion of the HIV into human host cells where it can replicate.
Buyer Products:
|
|
|
|
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.
Buyer Products:
|
|
|
|
Protease Inhibitors
Therapeutics that help manage HIV by binding to and blocking the action of HIV protease, an enzyme necessary for viral replication.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in very early stages of research where no human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Infectious Diseases |
|
|
|
Bacterial |
|
|
|
Antibacterial Agents |
|
|
|
Broad Spectrum |
|
|
|
Antibiotics |
|
|
|
Cephalosporin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Sulfonamides
Therapeutics that treat a wide variety of bacterial infections by inhibiting folic acid synthesis.
Buyer Products:
|
|
|
|
Narrow Spectrum |
|
|
|
Digestive System |
|
|
|
Shigellosis |
|
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat an infection of the intestines caused by Shigella by inhibiting folic acid synthesis.
Buyer Products:
|
|
|
|
Otolaryngology (Ear/Nose/Throat) |
|
|
|
Otitis Media |
|
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections leading to inflammation of the middle ear inhibiting certain enzymes that are vital for bacterial DNA transcription and repair.
Buyer Products:
|
|
|
|
Respiratory System |
|
|
|
Bronchitis |
|
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections leading to inflammation of the bronchi in the lungs by inhibiting certain enzymes that are vital for bacterial DNA transcription and repair.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Urinary Tract Infections (UTI) |
|
|
|
Antibacterial Agents (Antibiotics) |
|
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections of the urinary tract by inhibiting dihydrofolate reductase resulting in decreased bacterial nucleic acid/protein production.
Buyer Products:
|
|
|
|
Mycological (Fungal) |
|
|
|
Antifungal Agents |
|
|
|
Narrow Spectrum |
|
|
|
Respiratory System |
|
|
|
Pneumocystis Carinii Pneumonia (PCP) |
|
|
|
Dihydrofolate Reductase Inhibitors/Dihydropteroate Synthetase Inhibitors
Therapeutics that treat infections of the lungs of immunocompromised patients caused by Pneumocystis carinii by interfering with folic acid synthesis and growth of organism.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Protozoal |
|
|
|
Antiprotozoal Agents |
|
|
|
Narrow Spectrum |
|
|
|
Malaria |
|
|
|
Aminoquinolines
Therapeutics that treat parasitic infections caused by Plasmodia in red blood cells by inhibiting parasite growth.
Buyer Products:
|
|
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat infections due to parasites by inhibiting folic acid synthesis and also blocking the action of the dihydrofolate enzyme.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in very early stages of research where no human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Viral |
|
|
|
DNA Viruses |
|
|
|
Hepadnavirus |
|
|
|
Hepatitis B |
|
|
|
Chronic |
|
|
|
Interferons
Therapeutics that treat viral infections characterized by inflammation of the liver for more than six months with natural proteins that have antiviral activity.
Buyer Products:
|
|
|
|
Herpesvirus |
|
|
|
Cytomegalovirus (CMV) |
|
|
|
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.
Buyer Products:
|
|
|
|
RNA Viruses |
|
|
|
Flavivirus |
|
|
|
Hepatitis C |
|
|
|
Chronic |
|
|
|
Interferons
Therapeutics that treat hepatitis by providing a naturally occurring protein that stimulates the immune system.
Buyer Products:
|
|
|
|
Interferons/Nucleoside Analogs
Therapeutics that treat viral infections characterized by long term inflammation of the liver by enhancing the immune system and by inhibiting replication of viral DNA.
Buyer Products:
|
|
|
|
Orthomyxovirus |
|
|
|
Influenza A |
|
|
|
Neuraminidase Inhibitors
Therapeutics that treat viral infections of the respiratory tract caused by Influenza A virus by preventing the release of new viruses from infected cells.
Buyer Products:
|
|
|
|
Influenza B |
|
|
|
Neuraminidase Inhibitors
Therapeutics that treat viral infections of the respiratory tract caused by Influenza B virus by preventing the release of new viruses from infected cells.
Buyer Products:
|
|
|
|
Retrovirus |
|
|
|
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) |
|
|
|
Fusion Inhibitors
Therapeutics that manage HIV by inhibiting the fusion of the HIV into human host cells where it can replicate.
Buyer Products:
|
|
|
|
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.
Buyer Products:
|
|
|
|
Protease Inhibitors
Therapeutics that help manage HIV by binding to and blocking the action of HIV protease, an enzyme necessary for viral replication.
Buyer Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in very early stages of research where no human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Skeletal Disorders |
|
|
|
Bone Disorders |
|
|
|
Osteoporosis |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
Therapeutics that treat osteoporosis by providing female hormones which results in a decrease in the rate of bone loss due to osteoclasts.
Target Products:
|
|
|
|
Estrogens/Progestins
Therapeutics that treat osteoporosis by providing female hormones which results in a decrease in the rate of bone loss due to osteoclasts.
Target Products:
|
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat osteoporosis by preventing loss of bone mass due to osteoclasts.
Buyer Products:
|
|
|
|
Selective Estrogen Receptor Modulators (SERM)
Therapeutics that treat osteoporosis by preventing loss of bone mass due to osteoclasts while not stimulating the endometrial lining of the uterus.
Buyer Products:
|
|
|
|
Joint Disorders |
|
|
|
Ankylosing Spondylitis |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.
Buyer Products:
|
|
|
|
Gouty Arthritis |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by inhibiting cyclooxygenase activity.
Buyer Products:
|
|
|
|
Osteoarthritis (OA) |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.
Buyer Products:
|
|
|
|
Rheumatoid Arthritis (RA) |
|
|
|
Analgesics |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.
Buyer Products:
|
|
|
|
Immunotherapy |
|
|
|
Monoclonal Antibodies
Therapeutics that treat rheumatoid arthritis by interfering with specific immune pathways implicated in the progression of the disease.
Buyer Products:
|
|
|
|
Neurology |
|
|
|
Neurological Disorders |
|
|
|
Epilepsy |
|
|
|
Primary Generalized Seizures |
|
|
|
Absence (Petit Mal) |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.
Buyer Products:
|
|
|
|
Monotherapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.
Buyer Products:
|
|
|
|
Akinetic Pattern |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Akinetic Pattern Seizures by preventing the uptake of molecules that prevents nerve activation.
Buyer Products:
|
|
|
|
Monotherapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Akinetic
Pattern Seizures by preventing the uptake of molecules that prevents nerve activation.
Buyer Products:
|
|
|
|
Myoclonic |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Myoclonic Seizures by inhibiting the uptake of molecules that prevent nerve activation.
Buyer Products:
|
|
|
|
Monotherapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Myoclonic Seizures by inhibiting the uptake of molecules that prevents nerve activation.
Buyer Products:
|
|
|
|
Neuromuscular Disorders |
|
|
|
Multiple Sclerosis (MS) |
|
|
|
Interferons
Therapeutics that treat multiple sclerosis with a recombinant human protein that down regulates the antibody response of the immune system.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Psychiatric Disorders |
|
|
|
Anxiety |
|
|
|
Generalized Anxiety Disorder (GAD) |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat anxiety by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Buyer Products:
|
|
|
|
Panic Disorder |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat panic disorder by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Buyer Products:
|
|
|
|
Mood Disorders |
|
|
|
Premenstrual Dysphoric Disorders |
|
|
|
Estrogens/Progestins
Therapeutics that treat premenstrual dysphoric disorders by decreasing the secretion of gonadotropin-releasing hormone in the hypothalamus.
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Obstetrics/Gynecology |
|
|
|
Child Birth/Pregnancy |
|
|
|
Prevention (Contraception) |
|
|
|
Contraceptives (Birth Control) |
|
|
|
Estrogens/Progestins
Therapeutics that prevent conception by decreasing the secretion of gonadotropin-releasing hormone in the hypothalamus, resulting in an anti-ovulatory effect.
Target Products:
|
|
|
|
Progestins
Contraceptive Therapeutics that are female sex hormone necessary for the development of the female reproductive system
Target Products:
|
|
|
|
Female Genital Disorders |
|
|
|
Endometriosis |
|
|
|
Gonadotropin Releasing Hormone (GnRH) Agonists
Therapeutics that treat endometriosis by suppressing the secretion of luteinizing hormone which results in decreased testosterone concentrations.
Target Products:
|
|
|
|
Ovarian |
|
|
|
Hypogonadism |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
These are female sex hormones.
Target Products:
|
|
|
|
Vulvovaginal |
|
|
|
Atrophy |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
Therapeutics that treat disorders characterized by thinning of the vaginal walls with the female sex hormone estrogen.
Target Products:
|
|
|
|
Oncology |
|
|
|
Breast Cancer |
|
|
|
Localized |
|
|
|
Monoclonal Antibodies
Therapeutics that treat breast cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.
Buyer Products:
|
|
|
|
Metastatic |
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage breast cancers that have spread beyond their original tumor site by inhibiting the production of DNA.
Buyer Products:
|
|
|
|
Antimicrotubule Agents
Therapeutics that treat and manage cancers of the breast that have spread beyond their original tumor site by blocking the normal function of microtubules, thus inhibiting cell division.
Target Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that bind to specific receptors on the surface of breast cancer cells and inhibit the cancer cells' growth and induce their death.
Buyer Products:
|
|
|
|
Dermatology |
|
|
|
Kaposi`s Sarcoma |
|
|
|
Interferons
Therapeutics that treat and manage cancers of spindle cells by providing a naturally occurring protein that stimulates the immune system.
Buyer Products:
|
|
|
|
Digestive System |
|
|
|
Colon Cancer/Colorectal Cancer |
|
|
|
Localized |
|
|
|
Vascular Endothelial Growth Factor Receptor Inhibitor (VEGFR)
Therapeutics that treat colorrectal cancer by binding specifically to the tyrosine kinase domain of vascular endothelial growth factor receptor (VEGFR) and inhibiting the formation of blood vessels around tumor cells.
Target Products:
|
|
|
|
Metastatic |
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage colorectal tumors that have spread beyond their original tumor site by inhibiting the production of DNA.
Buyer Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that treat colorectal cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.
Buyer Products:
|
|
|
|
Vascular Endothelial Growth Factor Receptor Inhibitor (VEGFR) |
|
|
|
Pancreatic Cancer |
|
|
|
Metastatic |
|
|
|
Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitors
Therapeutics that treat and manage cancers of the pancreas by blocking the action of tyrosine kinase enzyme through switching off the signals from the epidermal growth factor receptors, which promote cell growth.
Buyer Products:
|
|
|
|
Hematology |
|
|
|
Leukemia |
|
|
|
Lymphoid |
|
|
|
Chronic |
|
|
|
Hairy Cell |
|
|
|
Interferons
A recombinantly produced protein normally produced by the body to fight viral infection used to treat and manage a slowly progressing cancer of lymphoid cells characterized by numerous irregular cytoplasmic projections.
Buyer Products:
|
|
|
|
Lymphocytic (CLL) |
|
|
|
Antimetabolite Agents |
|
|
|
Adenosine Deaminase Inhibitors
Therapeutics that treat and manage slowly progressing cancers of lymphocytic cells by inhibiting the transformation of deoxyadenosine into deoxyinosine thereby impairing DNA synthesis as well as leaving the cancer cells unable to repair single stranded DNA breaks.
Target Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that bind to specific receptors on the surface of leukemia cells and thereby induce their death.
Buyer Products:
Target Products:
|
|
|
|
Myeloid |
|
|
|
Acute |
|
|
|
Promyelocytic (APL) |
|
|
|
Retinoids/Vitamin A Analogs
Therapeutics that treat acute promyelocytic leukemia by helping in cell differentiation as well as decreasing proliferation of cells.
Buyer Products:
|
|
|
|
Chronic |
|
|
|
Myelogenous (CML) |
|
|
|
Interferons
Therapeutics that treat and manage slowly progressing cancers of myelogenous cells by providing a naturally occurring protein that stimulates the immune system.
Buyer Products:
|
|
|
|
Palliative Agents |
|
|
|
Colony Stimulating Factors (CSF) |
|
|
|
Granulocyte Macrophage (rhGM-CSF)
Therapeutics that treat neutropenia and other cancer related conditions by inducing the maturation and proliferation of granulocytes, macrophages and mixed granulocyte-macrophage colonies of cells.
Target Products:
|
|
|
|
Lymphoma |
|
|
|
Hodgkin`s Disease |
|
|
|
Palliative Agents |
|
|
|
Colony Stimulating Factors (CSF) |
|
|
|
Granulocyte Macrophage (rhGM-CSF)
Therapeutics that treat neutropenia and other cancer related conditions of lymphoma characterized by the presence of Reed-Sternberg cells by inducing the maturation and proliferation of granulocytes, macrophages and mixed granulocyte-macrophage colonies of cells.
Target Products:
|
|
|
|
Non-Hodgkin`s Lymphoma (NHL) |
|
|
|
Monoclonal Antibodies
Therapeutics that bind to specific receptors on the surface of lymphoma cells and thereby induce their death.
Buyer Products:
|
|
|
|
Palliative Agents |
|
|
|
Colony Stimulating Factors (CSF) |
|
|
|
Granulocyte Macrophage (rhGM-CSF)
Therapeutics that treat neutropenia and other cancer related conditions of lymphomas of B-cells and T-cells by inducing the maturation and proliferation of granulocytes, macrophages and mixed granulocyte-macrophage colonies of cells.
Target Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Metastatic |
|
|
|
Osteolytic Bone Metastases |
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat and manage bone cancers that have spread beyond their original tumor site by preventing the loss of bone mass followed by deposition of new bone which can result in entrapped tumors below the new bone surface.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer and are currently in an early research or preclinical stage of development.
Buyer Products:
|
|
|
|
Respiratory System/Thoracic |
|
|
|
Lung Cancer |
|
|
|
Non Small Cell Lung Cancer (NSCLC) |
|
|
|
Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitors
Therapeutics that treat and manage cancers of the lung including squamous cell carcinoma, adenocarcinoma and large cell carcinoma by blocking the tyrosine kinase enzyme by switching off the signals from the epidermal growth factor receptors.
Buyer Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that treat lung cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Kidney Cancer (Renal Cell Carcinoma) |
|
|
|
Metastatic |
|
|
|
Monoclonal Antibodies
Therapeutics that treat kidney cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.
Buyer Products:
|
|
|
|
Ovarian Cancer |
|
|
|
Adenocarcinoma |
|
|
|
Monoclonal Antibodies
Therapeutics that treat ovarian cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.
Buyer Products:
|
|
|
|
Uterine Cancer |
|
|
|
Uterine Fibroids (Leiomyoma, Uterus) |
|
|
|
Progestins Receptor Modulators
Therapeutics that treat and manage non-cancerous tumors of the uterus by modulating the effects of progesterone.
Target Products:
|
|
|
|
Ophthalmology |
|
|
|
Degenerative Disorders |
|
|
|
Macular Degeneration (AMD) |
|
|
|
Vascular Endothelial Growth Factor Inhibitors (VEGF)
Therapeutics that treat macular degeneration by binding to the vascular endothelial growth factor (VEGF) and inhibiting the formation of blood vessels in the eye.
Buyer Products:
|
|
|
|
Retinitis |
|
|
|
AIDS-Related Cytomegalovirus (CMV) Retinitis |
|
|
|
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of eye disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Pain Management |
|
|
|
Anesthesia |
|
|
|
General (Systemic) |
|
|
|
Adjunctive |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that result in anesthesia by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Buyer Products:
|
|
|
|
Reversal |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Antagonists
Therapeutics that reverse general anesthesia by competitively inhibiting benzodiapizines at the GABA receptors, thus reducing their effect and reversing the anesthesia.
Buyer Products:
|
|
|
|
Non-Narcotics |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain by non-specifically inhibiting the action of cyclooxygenase.
Buyer Products:
|
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) Combinations |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID)/Decongestants
Therapeutic combinations that produce insensibility or numbness through the inhibition of prostoglandins while also preventing nasal decongestion.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of pain in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Respiratory System |
|
|
|
Lower Respiratory Tract Disorders (Lung Disorders) |
|
|
|
Asthma |
|
|
|
Prophylactic Treatments |
|
|
|
Monoclonal Antibodies
Therapeutics that treat asthma with monoclonal antibodies.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in very early stages of research where no human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Surgery |
|
|
|
Cardiovascular System |
|
|
|
Complications |
|
|
|
Peripheral Arterial Occlusion |
|
|
|
Thrombolytic Agents
Therapeutics that treat diseases of the blood vessels outside the heart by dissolving blood clots.
Buyer Products:
|
|
|
|
Toxicology |
|
|
|
Substance Abuse |
|
|
|
Withdrawal |
|
|
|
Alcohol |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat alcohol withdrawal by increasing the effect of GABA at the relevant neuroreceptors.
Buyer Products:
|
|
|
|
Transplantation |
|
|
|
Bone Marrow |
|
|
|
Complications |
|
|
|
Cytomegalovirus (CMV) Infections |
|
|
|
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.
Buyer Products:
|
|
|
|
Neutropenia |
|
|
|
Colony Stimulating Factors (CSF) |
|
|
|
Granulocyte Macrophage (rhGM-CSF)
Therapeutics containing biological proteins that stimulate the formation of certain white blood cell colonies.
Target Products:
|
|
|
|
Heart |
|
|
|
Complications |
|
|
|
Cytomegalovirus (CMV) Infections |
|
|
|
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.
Buyer Products:
|
|
|
|
Rejection Prophylaxis |
|
|
|
Immunosuppressants
Therapeutics that help manage and suppress the response of the immune system to foreign tissue.
Buyer Products:
|
|
|
|
Hepatic (Liver) |
|
|
|
Complications |
|
|
|
Cytomegalovirus (CMV) Infections |
|
|
|
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.
Buyer Products:
|
|
|
|
Rejection Prophylaxis |
|
|
|
Immunosuppressants
Therapeutics that manage and suppress the response of the immune system to foreign tissue.
Buyer Products:
|
|
|
|
Lung |
|
|
|
Complications |
|
|
|
Cytomegalovirus (CMV) Infections |
|
|
|
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.
Buyer Products:
|
|
|
|
Pancreas |
|
|
|
Complications |
|
|
|
Cytomegalovirus (CMV) Infections |
|
|
|
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.
Buyer Products:
|
|
|
|
Peripheral Blood Progenitor Cell Transplant (PBPCT) |
|
|
|
Recovery |
|
|
|
Colony Stimulating Factors (CSF) |
|
|
|
Granulocyte Macrophage (rhGM-CSF)
Therapeutics containing biological proteins that stimulate the formation of certain white blood cell colonies.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the management of rejection and infection in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Renal (Kidney) |
|
|
|
Complications |
|
|
|
Cytomegalovirus (CMV) Infections |
|
|
|
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.
Buyer Products:
|
|
|
|
Rejection Prophylaxis |
|
|
|
Immunosuppressants
Therapeutics that manage and suppress the response of the immune system to foreign tissue.
Buyer Products:
|
|
|
|
Monoclonal Antibodies
Protein-based therapeutics that target specific substances like proteins.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Urological Disorders |
|
|
|
Kidney (Renal) |
|
|
|
Chronic Renal Failure (CRF) |
|
|
|
Complications |
|
|
|
Anemia |
|
|
|
Recombinant Human Erythropoietins
Therapeutics that treat the condition resulting from the scarcity of red blood cells by inducing the production of red blood cells.
Buyer Products:
|
|
|
|
Edema |
|
|
|
Loop Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissues by promoting the excretion of urine.
Buyer Products:
|
|
|
|
Weight Management |
|
|
|
Obesity |
|
|
|
Lipase Inhibitors
Therapeutics that reduce the absorption of fat by inhibiting production of lipase, which is an enzyme that helps breaking down fat in the food.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of weight disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of weight disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Wound Management |
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of wounds in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Medical Devices |
|
|
|
Cardiology |
|
|
|
Diagnostic |
|
|
|
Imaging |
|
|
|
Magnetic Resonance Imaging (MRI) |
|
|
|
Contrast Agents
A drug that is introduced into a patient to attain better image quality.
Target Products:
|
|
|
|
X-Ray |
|
|
|
Angiography |
|
|
|
Accessories
Various instruments used to assist in angiography procedures, including transducers, catheters, control syringes, waste systems, contrast management systems, fluid administration sets, and other related items.
Target Products:
|
|
|
|
Monitoring |
|
|
|
Monitors |
|
|
|
Vitals/Multiple Parameter |
|
|
|
Electrocardiogram (ECG/EKG)/Pulse Oximeter (SpO2)/ Multiple Vitals |
|
|
|
Portable
Device that measures, records, and displays the electrical signals of the heart, the oxygen concentration in the blood, the blood pressure with direct access to an artery and blood pressure with out direct access to an artery and can be moved around with the patient.
Target Products:
|
|
|
|
Clinical Diagnostics |
|
|
|
Chemistry |
|
|
|
Analyzers |
|
|
|
Blood Gas
Analyzers used to measure blood gases for diagnostic purposes.
Buyer Products:
|
|
|
|
Discrete |
|
|
|
Limited Assay
Discrete analyzers with limited test menu.
Buyer Products:
|
|
|
|
Multiple Assay
Multi-System analyzers designed for high throughput generally used in high volume clinical laboratories.
Buyer Products:
|
|
|
|
Home Testing |
|
|
|
Cholesterol
Home test kits which test for cholesterol levels in patient blood.
Buyer Products:
|
|
|
|
Glucose |
|
|
|
Invasive
Devices that generally use blood samples for testing and require a needlestick or pin-prick.
Buyer Products:
|
|
|
|
Test Strips
Specific glucose test devices used with glucose monitors.
Buyer Products:
|
|
|
|
Point of Care Testing |
|
|
|
Critical Care Analysis |
|
|
|
Analyzers
Chemistry analyzers which may be used for the chemical analysis of body fluids and designed for use at the bedside during the course of patient care.
Buyer Products:
|
|
|
|
Test Cartridges
Specific analyte test devices used in conjunction with critical care chemistry analyzers.
Buyer Products:
|
|
|
|
Glucose Monitoring |
|
|
|
Invasive |
|
|
|
Continuous Analysis
Glucose test devices which measure patient glucose levels on a continual basis.
Buyer Products:
|
|
|
|
Random Analysis
Glucose test devices which measure patient glucose levels as a blood sample is obtained.
Buyer Products:
|
|
|
|
Kits |
|
|
|
Cardiac
Test kits used to aid in the diagnosis of heart conditions.
Buyer Products:
|
|
|
|
Reagents |
|
|
|
Calibrators |
|
|
|
Routine Analyte |
|
|
|
Multiple
Calibrators which contain multiple specific analytes used to establish the accuracy of chemistry analyzers.
Buyer Products:
|
|
|
|
Single
Calibrators which contain a specific analyte used to establish the accuracy of chemistry analyzers.
Buyer Products:
|
|
|
|
Controls |
|
|
|
Routine
Controls used to test the accuracy of discrete chemistry test systems.
Buyer Products:
|
|
|
|
Test Kits |
|
|
|
Pharmacogenetic
Test kits designed to determine individuals' reaction to specific medications based on their specific genes.
Buyer Products:
|
|
|
|
Hemostasis/Coagulation |
|
|
|
Analyzers |
|
|
|
Automated
Automated coagulation analyzers.
Buyer Products:
|
|
|
|
Reagents |
|
|
|
Test Kits |
|
|
|
Prothrombin Time
Reagents used to perform prothrombin time assays.
Buyer Products:
|
|
|
|
Immunoassays |
|
|
|
Analyzers |
|
|
|
Autoimmune
Analyzers used to perform autoimmune testing.
Buyer Products:
|
|
|
|
Multiple Assay
Immunoassay analyzer designed to perform multiple assays over multiple modalities.
Buyer Products:
|
|
|
|
Reagents |
|
|
|
Calibrators |
|
|
|
Therapeutic Drugs
Calibrators used in the measurement of therapeutic drugs.
Buyer Products:
|
|
|
|
Toxicology/Abuse Drugs
Calibrators used in the measurement of drugs of abuse.
Buyer Products:
|
|
|
|
Controls |
|
|
|
Therapeutic Drugs
Controls which contain known concentrations of specific therapeutic drugs used to verify the performance of therapeutic drug testing systems.
Buyer Products:
|
|
|
|
Test Kits |
|
|
|
Bacterial |
|
|
|
Chlamydia
Immunoassay kits which test for current or previous infection caused by the Chlamydia organism.
Buyer Products:
|
|
|
|
Tuberculosis
Immunoassay test kits which quantitatively measure tuberculosis antibody in plasma or serum.
Buyer Products:
|
|
|
|
Radioimmunoassays |
|
|
|
Cancer Marker
Radioimmunoassay test kits which measure for cancer markers in plasma or serum.
Buyer Products:
|
|
|
|
Cardiac
Radioimmunoassay test kits which measure for analytes associated with heart disease in plasma or serum.
Buyer Products:
|
|
|
|
Special/Immuno Chemistry |
|
|
|
Cancer Marker |
|
|
|
Breast
Diagnostic assay used to detect specific breast tumor or cancer markers.
Buyer Products:
|
|
|
|
Colorectal (Colon)
Diagnostic assay used to detect specific colorectal (colon) tumor or cancer markers.
Buyer Products:
|
|
|
|
Cardiac |
|
|
|
Myocardial Infarction/Heart Failure |
|
|
|
Myoglobin
Immunoassay test kits which quantitatively measure for myoglobin in plasma or serum.
Buyer Products:
|
|
|
|
Troponin
Immunoassay test kits which quantitatively measure for troponin in plasma or serum.
Buyer Products:
|
|
|
|
Therapeutic Drugs
Immunoassay test kits which quantitatively measure for therapeutic drugs in serum or urine using automated instrumentation..
Buyer Products:
|
|
|
|
Toxicology/Abuse Drugs |
|
|
|
Multiple Drug Kit
Immunoassay test kits which measure for more than one drug of abuse in body fluids.
Buyer Products:
|
|
|
|
Viral |
|
|
|
Human Immunodeficiency Virus (HIV) |
|
|
|
Serum |
|
|
|
Genotyping
Tests that "fingerprint" HIV according to chromosomal makeup in order to track specific strains.
Buyer Products:
|
|
|
|
Microbiology |
|
|
|
Genetic Probes/PCR |
|
|
|
Reagents |
|
|
|
Bacterial |
|
|
|
Tuberculosis
Genetic probe for detection and/or quantitation of Mycobacterium tuberculosis.
Buyer Products:
|
|
|
|
Viral |
|
|
|
Cytomegalovirus
Genetic probe for detection and/or quantitation of Cytomegalovirus.
Buyer Products:
|
|
|
|
Hepatitis B Virus
Genetic probes for detection and/or quantitation of HBV.
Buyer Products:
|
|
|
|
Hepatitis C Virus
Genetic probes for detection and/or quantitation of HCV.
Buyer Products:
|
|
|
|
Human Immunodeficiency Virus (HIV)
Genetic probes for detection and quantification of HIV.
Buyer Products:
|
|
|
|
Human Papilloma Virus
Genetic probes for the detection of HPV.
Buyer Products:
|
|
|
|
West Nile Virus
Genetic probe for detection and/or quantitation of West Nile Virus.
Buyer Products:
|
|
|
|
Specimen Collection |
|
|
|
Blood |
|
|
|
Capillary |
|
|
|
Lancets
Sharps type of device used to puncture the skin in order to collect a capillary blood sample.
Buyer Products:
|
|
|
|
Urinalysis |
|
|
|
Analyzers |
|
|
|
Chemistry
Analyzers used to perform chemical analysis of urine.
Buyer Products:
|
|
|
|
Reagents |
|
|
|
Test Strips
Reagents, in a embedded strip format, used to perform chemical, and physical analysis of urine or body fluids.
Buyer Products:
|
|
|
|
Neurology |
|
|
|
Surgical |
|
|
|
Region Specific |
|
|
|
Brain |
|
|
|
Stereotactic Surgery |
|
|
|
Guidance/ Planning Systems
Imaging equipment and/or computer systems that create a 3D map of the interior of the brain facilitating stereotactic surgery.
Target Products:
|
|
|
|
Oncology |
|
|
|
Diagnostic |
|
|
|
Imaging |
|
|
|
MRI |
|
|
|
Contrast Agents
A drug that is introduced into a patient to attain better MRI image quality.
Target Products:
|
|
|
|
Radiology |
|
|
|
Computed Tomography (CT) Scan |
|
|
|
Accessories |
|
|
|
CT Contrast Injectors
Devices that mechanically push contrast agent into the patient.
Target Products:
|
|
|
|
Syringes
Disposables used in contrast injection pumps.
Target Products:
|
|
|
|
Contrast Agents |
|
|
|
Injectable
CT Scan contrast agents administered by injection.
Target Products:
|
|
|
|
MRI |
|
|
|
Accessories |
|
|
|
Needle Systems
Injection systems used to deliver MRI contrast agents.
Target Products:
|
|
|
|
Coils |
|
|
|
Closed MRI |
|
|
|
General Purpose
A closed MRI system that is designed to be used for multiple purpose imaging studies.
Target Products:
|
|
|
|
Region Specific |
|
|
|
Abdominal
A coil that is placed on the abdomen to attain an image.
Target Products:
|
|
|
|
Breast
A coil that is placed on the breast to attain an image of it.
Target Products:
|
|
|
|
Head/Neck
A coil that is placed on or around the head/neck to attain an image of it.
Target Products:
|
|
|
|
Lower Extremity
A coil that is placed on the lower extremity to attain an image of it.
Target Products:
|
|
|
|
Spine
A coil that is placed near the spine to attain an image of it.
Target Products:
|
|
|
|
Upper Extremity
A coil that is placed on an upper extremity to attain an image of it.
Target Products:
|
|
|
|
Vascular
A coil that is placed near a vessel to attain an image of it.
Target Products:
|
|
|
|
Contrast Agents |
|
|
|
Injectable
A contrast agent that gets introduced to the body via a needle or IV.
Target Products:
|
|
|
|
Ultrasound |
|
|
|
Accessories |
|
|
|
Aspiration Needles
Biopsy needles that have special properties allowing ultrasound guidance.
Target Products:
|
|
|
|
X-Ray |
|
|
|
Contrast Agents |
|
|
|
Injectable
Introduced to the body via a needle.
Target Products:
|
|
|
|
Urology |
|
|
|
Diagnostic |
|
|
|
Imaging |
|
|
|
MRI |
|
|
|
Contrast Agents
A drug that is introduced into a patient to attain better MRI image quality.
Target Products:
|
|
|
|
Vascular |
|
|
|
Diagnostic |
|
|
|
Imaging |
|
|
|
X-Ray |
|
|
|
Angiography |
|
|
|
Accessories
Various instruments used to assist in angiography procedures, including transducers, catheters, control syringes, waste systems, contrast management systems, fluid administration sets, and other related items.
Target Products:
|
|
|
|
Scientific Products |
|
|
|
Analytical Instruments |
|
|
|
Analyzers |
|
|
|
Gas Monitors |
|
|
|
Multiple Component |
|
|
|
Benchtop
Multi-component gas monitors that are generally located on the counter top.
Buyer Products:
|
|
|
|
Bioanalytical Instruments |
|
|
|
Biomolecular |
|
|
|
Microplate Readers |
|
|
|
Systems |
|
|
|
Multiple Parameter
Microplate reader systems that used a combination of fluorescent, luminescent, and/or photoemission detectors.
Buyer Products:
|
|
|
|
Sequencers |
|
|
|
Automated |
|
|
|
Nucleic Acid
Automated gel electrophoresis or capillary electrophoresis sequencers used to analyze nucleic acid sample.
Buyer Products:
|
|
|
|
Synthesizers |
|
|
|
Peptides
Synthesizer systems used for the identification and synthesis of peptide samples.
Buyer Products:
|
|
|
|
Thermal Cyclers |
|
|
|
Accessories
Supplementary products used to enhance the performance of a thermal cycler.
Buyer Products:
|
|
|
|
Systems
Thermal cycler components assembled as a single unit.
Buyer Products:
|
|
|
|
Consumables |
|
|
|
Bioanalytical Chemistry |
|
|
|
Molecular Biology |
|
|
|
Microarray Technology |
|
|
|
Microarray Chips
Microarray/biochip components that give detailed analysis of differential expression in normal and diseased or treated cells.
Buyer Products:
|
|
|
|
Nucleic Acid Analysis |
|
|
|
Kits |
|
|
|
Nucleic Acid |
|
|
|
Transfection
Nucleic acid analysis kits that are used for the introduction of DNA into a recipient eukaryote cell and its subsequent integration into the recipient cells chromosomal DNA
Buyer Products:
|
|
|
|
General Laboratory Equipment |
|
|
|
Automation Equipment |
|
|
|
Robotic Instruments |
|
|
|
Workstations
Robotic instrument systems that transfer liquid and gas samples and also heat and cool samples.
Buyer Products:
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Relationship Details
Key Competitors
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
Amgen, Inc.
|
|
n/a | 84,572.553 | 28.76 | 19.18 | 6.17 | 5.98 | 31.37 | |
|
Biogen Idec Inc.
|
|
n/a | 17,365.400 | 105.62 | 24.29 | 6.66 | 6.52 | 5.90 | |
|
Serono S.A. (ADR)
|
|
n/a | 13,657.170 | 19.97 | 19.08 | 4.99 | 4.87 | 5.65 | |
|
Altana AG (ADR)
|
|
n/a | 7,901.267 | 12.40 | 13.47 | 3.28 | n/a | 3.62 | |
|
Barr Pharmaceuticals, Inc.
|
|
n/a | 5,376.860 | 17.57 | 15.38 | 4.02 | 3.70 | 4.32 | |
|
The Medicines Company
|
|
n/a | 1,388.930 | 318.19 | 90.77 | 7.48 | 6.53 | 6.95 | |
|
GPC Biotech AG (ADR)
|
|
n/a | 681.567 | n/a | n/a | 26.01 | n/a | 6.76 | |
|
Neurocrine Biosciences, Inc.
|
|
n/a | 378.840 | n/a | -3.13 | 8.63 | 11.84 | 1.16 | |
|
Immunomedics, Inc.
|
|
n/a | 152.476 | n/a | n/a | 21.00 | n/a | n/a | |
|
Point Therapeutics, Inc.
|
|
n/a | 30.471 | n/a | -0.99 | 101.09 | 57.66 | 1.44 | |
| Buyer | |||||||||
|
Pfizer Inc.
|
|
n/a | 193,888.862 | 15.37 | 13.35 | 4.01 | 4.07 | 8.31 | |
|
Johnson & Johnson
|
|
n/a | 190,922.506 | 17.25 | 17.85 | 3.65 | 3.63 | 7.01 | |
| Target | |||||||||
|
Roche Holding Ltd. (ADR)
|
|
n/a | 157,245.145 | 34.89 | 24.82 | 5.69 | n/a | 8.62 | |
|
Genentech, Inc.
|
|
n/a | 84,941.939 | 45.71 | 40.64 | 10.04 | 9.42 | 12.00 | |
|
Amgen, Inc.
|
|
n/a | 84,572.553 | 28.76 | 19.18 | 6.17 | 5.98 | 31.37 | |
|
Teva Pharmaceutical Industries Ltd (ADR)
|
|
n/a | 25,046.770 | 64.06 | 14.03 | 3.33 | 2.95 | 34.79 | |
|
Biogen Idec Inc.
|
|
n/a | 17,365.400 | 105.62 | 24.29 | 6.66 | 6.52 | 5.90 | |
|
Serono S.A. (ADR)
|
|
n/a | 13,657.170 | 19.97 | 19.08 | 4.99 | 4.87 | 5.65 | |
|
Altana AG (ADR)
|
|
n/a | 7,901.267 | 12.40 | 13.47 | 3.28 | n/a | 3.62 | |
|
Elan Corporation, plc (ADR)
|
|
n/a | 6,402.804 | n/a | -19.09 | 11.98 | 11.94 | n/a | |
|
Barr Pharmaceuticals, Inc.
|
|
n/a | 5,376.860 | 17.57 | 15.38 | 4.02 | 3.70 | 4.32 | |
|
Warner Chilcott Ltd.
|
|
n/a | 3,397.557 | n/a | 24.98 | 4.95 | 4.66 | n/a | |
|
Medicis Pharmaceutical Corporation
|
|
n/a | 2,078.941 | n/a | 48.94 | 6.28 | 5.89 | 8.62 | |
|
MGi Pharma, Inc.
|
|
n/a | 1,532.097 | n/a | -107.28 | 4.46 | 4.36 | n/a | |
|
The Medicines Company
|
|
n/a | 1,388.930 | 318.19 | 90.77 | 7.48 | 6.53 | 6.95 | |
- Defined by the Company
- Defined by Others
Dependent Suppliers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
|
Biogen Idec Inc.
|
|
n/a | 17,365.400 | 105.62 | 24.29 | 6.66 | 6.52 | 5.90 | |
|
Serono S.A. (ADR)
|
|
n/a | 13,657.170 | 19.97 | 19.08 | 4.99 | 4.87 | 5.65 | |
|
Crucell N.V. (ADR)
|
|
n/a | 1,397.634 | n/a | -13.44 | 14.23 | 7.49 | 3.80 | |
|
Dendrite International, Inc.
|
|
n/a | 511.778 | n/a | 53.45 | 1.22 | 1.23 | 3.77 | |
|
Bioject Medical Technologies Inc.
|
|
n/a | 14.847 | n/a | n/a | 1.55 | n/a | 2.54 | |
| Buyer | |||||||||
|
Aspreva Pharmaceuticals Corporation
|
|
100.00% | 668.666 | 5.46 | 5.88 | 3.22 | 3.18 | 2.62 | |
|
Emisphere Technologies Inc.
|
|
80.40% | 164.318 | n/a | -4.88 | 23.04 | 48.40 | n/a | |
|
deCODE genetics, Inc.
|
|
23.00% | 292.909 | n/a | -3.39 | 7.54 | 7.32 | n/a | |
|
PDL BioPharma Inc.
|
|
3.30% | 2,676.705 | n/a | 90.04 | 6.85 | 6.27 | 26.44 | |
|
sanofi-aventis (ADR)
|
|
n/a | 116,539.433 | 30.70 | 13.50 | 3.12 | 3.28 | n/a | |
| Target | |||||||||
|
Advanced Magnetics, Inc.
|
|
47.00% | 683.619 | n/a | -60.21 | 250.37 | 498.12 | 15.35 | |
|
Biogen Idec Inc.
|
|
n/a | 17,365.400 | 105.62 | 24.29 | 6.66 | 6.52 | 5.90 | |
|
Serono S.A. (ADR)
|
|
n/a | 13,657.170 | 19.97 | 19.08 | 4.99 | 4.87 | 5.65 | |
|
Millennium Pharmaceuticals, Inc.
|
|
n/a | 3,612.192 | n/a | -286.50 | 7.70 | 7.57 | 6.47 | |
|
Medarex, Inc.
|
|
n/a | 1,644.559 | n/a | -9.34 | 29.36 | 34.19 | 4.46 | |
|
Crucell N.V. (ADR)
|
|
n/a | 1,397.634 | n/a | -13.44 | 14.23 | 7.49 | 3.80 | |
|
Dendrite International, Inc.
|
|
n/a | 511.778 | n/a | 53.45 | 1.22 | 1.23 | 3.77 | |
|
Penwest Pharmaceuticals
|
|
n/a | 422.847 | n/a | -13.24 | 114.56 | 110.91 | 8.71 | |
|
OPNET Technologies, Inc.
|
|
n/a | 332.082 | 60.23 | 43.76 | 3.79 | 3.42 | 3.71 | |
|
Peregrine Pharmaceuticals
|
|
n/a | 246.122 | n/a | n/a | 72.26 | n/a | 8.49 | |
|
EPIX Pharmaceuticals, Inc.
|
|
n/a | 125.667 | n/a | -2.99 | 20.31 | 15.99 | n/a | |
|
Pharmacopeia Drug Discovery, Inc.
|
|
n/a | 85.337 | n/a | -2.54 | 4.44 | 4.80 | 4.51 | |
|
Bioject Medical Technologies Inc.
|
|
n/a | 14.847 | n/a | n/a | 1.55 | n/a | 2.54 | |
|
Tripos, Inc.
|
|
n/a | 7.810 | n/a | n/a | 0.18 | n/a | 0.38 | |
|
Valentis, Inc.
|
|
n/a | 7.687 | n/a | n/a | 10.58 | n/a | 3.16 | |
- Defined by the Company
- Defined by Others
Key Customers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Applera Corporation
|
|
n/a | 6,752.947 | 38.97 | 27.64 | 3.42 | 3.31 | 5.91 | |
|
PDL BioPharma Inc.
|
|
n/a | 2,676.705 | n/a | 90.04 | 6.85 | 6.27 | 26.44 | |
|
MDS Inc. (USA)
|
|
n/a | 2,667.679 | 67.96 | 30.20 | 1.99 | 2.14 | 4.78 | |
|
IDEXX Laboratories, Inc.
|
|
n/a | 2,650.065 | 29.77 | 31.15 | 3.71 | 3.61 | 10.40 | |
|
Gen-Probe Incorporated
|
|
n/a | 2,617.338 | 43.60 | 45.06 | 7.44 | 7.38 | 5.23 | |
|
Aspreva Pharmaceuticals Corporation
|
|
n/a | 668.666 | 5.46 | 5.88 | 3.22 | 3.18 | 2.62 | |
|
Connetics Corporation
|
|
n/a | 597.988 | n/a | -28.85 | 4.10 | 3.60 | n/a | |
|
Grupo Casa Saba, S.A. (ADR)
|
|
n/a | 592.947 | 8.35 | n/a | 0.28 | n/a | 1.31 | |
|
Abaxis, Inc.
|
|
n/a | 415.428 | 47.80 | 43.63 | 5.28 | n/a | 5.29 | |
|
Enzon Pharmaceuticals, Inc.
|
|
n/a | 368.304 | n/a | 16.78 | 2.19 | 1.99 | n/a | |
|
Trimeris, Inc.
|
|
n/a | 255.860 | 39.63 | 50.91 | 9.35 | 7.57 | 8.86 | |
|
IRIS International, Inc.
|
|
n/a | 166.138 | 357.61 | 31.73 | 2.52 | 2.43 | 3.14 | |
|
Allion Healthcare, Inc.
|
|
n/a | 96.572 | 26.56 | 27.00 | 0.51 | 0.44 | 3.43 | |
| Target | |||||||||
|
Millennium Pharmaceuticals, Inc.
|
|
n/a | 3,612.192 | n/a | -286.50 | 7.70 | 7.57 | 6.47 | |
|
Cotherix, Inc
|
|
n/a | 384.762 | n/a | -14.06 | 6.41 | 5.57 | 4.49 | |
|
Sonus Pharmaceuticals, Inc.
|
|
n/a | 213.430 | n/a | -7.65 | 8.62 | 8.95 | 4.34 | |
|
Favrille, Inc.
|
|
n/a | 101.704 | n/a | -2.25 | n/a | n/a | 1.89 | |
|
Accentia Biopharmaceuticals, Inc
|
|
n/a | 100.865 | n/a | -2.34 | 3.72 | 3.31 | n/a | |
- Defined by the Company
- Defined by Others
Key Partners
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
|
Novartis AG (ADR)
|
|
n/a | 137,962.635 | 20.11 | 18.92 | 3.81 | 3.74 | 3.58 | |
|
Biogen Idec Inc.
|
|
n/a | 17,365.400 | 105.62 | 24.29 | 6.66 | 6.52 | 5.90 | |
|
Serono S.A. (ADR)
|
|
n/a | 13,657.170 | 19.97 | 19.08 | 4.99 | 4.87 | 5.65 | |
|
Medarex, Inc.
|
|
n/a | 1,644.559 | n/a | -9.34 | 29.36 | 34.19 | 4.46 | |
|
Valentis, Inc.
|
|
n/a | 7.687 | n/a | n/a | 10.58 | n/a | 3.16 | |
| Buyer | |||||||||
|
GlaxoSmithKline plc (ADR)
|
|
n/a | 148,888.977 | 14.59 | 14.60 | 3.36 | 3.42 | 14.57 | |
|
Novartis AG (ADR)
|
|
n/a | 137,962.635 | 20.11 | 18.92 | 3.81 | 3.74 | 3.58 | |
| Target | |||||||||
|
Pfizer Inc.
|
|
n/a | 193,888.862 | 15.37 | 13.35 | 4.01 | 4.07 | 8.31 | |
|
Novartis AG (ADR)
|
|
n/a | 137,962.635 | 20.11 | 18.92 | 3.81 | 3.74 | 3.58 | |
|
AstraZeneca plc (ADR)
|
|
n/a | 89,001.730 | 15.25 | 14.69 | 3.48 | 3.38 | 8.92 | |
|
Abbott Laboratories
|
|
n/a | 72,061.862 | 22.74 | 18.94 | 3.23 | 3.25 | 28.77 | |
|
3M Company
|
|
n/a | 59,756.110 | 17.39 | 17.98 | 2.66 | 2.62 | 9.21 | |
|
Koninklijke Philips Electronics NV (ADR)
|
|
n/a | 43,560.190 | 6.91 | 33.58 | 1.23 | 1.30 | 1.83 | |
|
Biogen Idec Inc.
|
|
n/a | 17,365.400 | 105.62 | 24.29 | 6.66 | 6.52 | 5.90 | |
|
Genzyme Corporation
|
|
n/a | 17,130.299 | 47.84 | 29.82 | 5.60 | 5.42 | 5.69 | |
|
Serono S.A. (ADR)
|
|
n/a | 13,657.170 | 19.97 | 19.08 | 4.99 | 4.87 | 5.65 | |
|
Vertex Pharmaceuticals Incorporated
|
|
n/a | 5,639.027 | n/a | -22.12 | 30.34 | 26.84 | 11.11 | |
|
Millennium Pharmaceuticals, Inc.
|
|
n/a | 3,612.192 | n/a | -286.50 | 7.70 | 7.57 | 6.47 | |
|
Warner Chilcott Ltd.
|
|
n/a | 3,397.557 | n/a | 24.98 | 4.95 | 4.66 | n/a | |
|
Bausch & Lomb Inc.
|
|
n/a | 2,676.622 | 17.99 | 72.25 | 1.14 | 1.14 | 4.69 | |
|
Medarex, Inc.
|
|
n/a | 1,644.559 | n/a | -9.34 | 29.36 | 34.19 | 4.46 | |
|
Pharmion Corporation
|
|
n/a | 741.256 | n/a | -53.34 | 3.15 | 3.18 | 3.38 | |
|
Advanced Magnetics, Inc.
|
|
n/a | 683.619 | n/a | -60.21 | 250.37 | 498.12 | 15.35 | |
|
Penwest Pharmaceuticals
|
|
n/a | 422.847 | n/a | -13.24 | 114.56 | 110.91 | 8.71 | |
|
Indevus Pharmaceuticals
|
|
n/a | 403.455 | n/a | -7.71 | 8.89 | 8.48 | n/a | |
- Defined by the Company
- Defined by Others
Financials
| Buyer | Target | Combined Entity | |
|---|---|---|---|
| Income Statement | |||
| Operating Items | |||
| Revenue | 27,655.5 | 7,009.5 | 34,664.9 |
|
Other Revenue
|
0.0 | 0.0 | 0.0 |
| Total Revenue | 27,655.5 | 7,009.5 | 34,664.9 |
|
Cost of Revenue
|
7,245.8 | 1,624.0 | 8,869.9 |
|
SG&A Expense
|
9,277.7 | 2,887.9 | 12,165.5 |
|
Depreciation & Amortization
|
787.4 | 0.0 | 787.4 |
|
Research & Development
|
4,443.0 | 1,283.9 | 5,726.9 |
|
Interest Expense
|
0.0 | 0.0 | 0.0 |
|
Other Operating Expense
|
-1,126.9 | 119.2 | -1,007.7 |
|
Unusual Expense (Income)
|
277.2 | 0.0 | 277.2 |
| Total Expenses | 20,904.2 | 5,915.1 | 26,819.2 |
|
Operating Income
|
6,751.3 | 1,094.4 | 7,845.7 |
| Non Operating Items | |||
|
Interest Expense (Inc.), Net Non-Oprtng
|
231.3 | 18.8 | 250.1 |
|
Other, Net
|
0.0 | 28.9 | 28.9 |
| Income Before Taxes | 6,982.6 | 1,142.1 | 8,124.7 |
| Income Taxes | 1,732.0 | 384.0 | 2,116.1 |
| Income After Taxes | 5,250.6 | 758.1 | 6,008.6 |
| Minority Interest (IS) | -734.4 | -5.0 | -739.4 |
|
Net Income - Excl. Xord. Items
|
4,516.2 | 753.0 | 5,269.2 |
| Discontinued Operations | -9.3 | 0.0 | -9.3 |
|
Net Income - Incl. Xord. Items
|
4,506.8 | 753.0 | 5,259.9 |
|
Income Avail. to Common
|
4,506.8 | 753.0 | 5,259.9 |
| Share Items | |||
|
Basic Avg. Shares Outstanding
|
1,690.0 | 192.4 | 1,882.4 |
|
Basic EPS - Excl. Xord. Items
|
5.34 | 3.91 | 2.80 |
|
Basic EPS - Incl. Xord. Items
|
2.67 | 3.91 | 2.79 |
| Full Dilution Adjustment | 0.0 | 0.0 | 0.0 |
| Fully Diluted Shares Outstanding | 1,720.0 | 192.4 | 1,912.4 |
|
F.D. EPS - Excl. Xord. Items
|
2.63 | 3.91 | 2.76 |
|
F.D. EPS - Incl. Xord. Items
|
2.62 | 3.91 | 2.75 |
| Dividends Per Common Share | 0.97 | 1.51 | 2.48 |
| Balance Sheet | |||
| Assets | |||
|
Cash and Equivalents
|
3,292.7 | 1,445.8 | 4,738.5 |
|
ST Investments
|
12,972.2 | 94.1 | 13,066.4 |
|
Accounts Receivable
|
5,995.1 | 1,865.0 | 7,860.1 |
|
Inventory
|
3,925.9 | 1,070.6 | 4,996.4 |
|
Other Current Assets
|
1,559.1 | 0.0 | 1,559.1 |
|
Current Assets
|
27,745.0 | 4,475.5 | 32,220.5 |
|
Accum D&A
|
0.0 | 0.0 | 0.0 |
|
PPE, Net
|
11,757.3 | 1,408.2 | 13,165.5 |
| Goodwill & Intangibles | 9,647.6 | 829.6 | 10,477.2 |
| Long Term Investments | 1,750.7 | 268.6 | 2,019.3 |
| Other Assets | 0.0 | 0.0 | 0.0 |
|
Other LT Assets
|
3,119.8 | 396.6 | 3,516.4 |
| Total Assets | 54,020.5 | 7,378.4 | 61,398.9 |
| Liabilities | |||
| Accounts Payable | 1,848.1 | 0.0 | 1,848.1 |
| Payable/Accrued | 0.0 | 0.0 | 0.0 |
| Accrued Expenses | 3,992.8 | 0.0 | 3,992.8 |
|
ST Debt
|
0.0 | 0.0 | 0.0 |
|
Curr Port of LTD & Cap Lease Oblg
|
271.0 | 30.1 | 301.1 |
| Other (Current) Liabilities | 1,280.3 | 1,907.7 | 3,188.0 |
|
Current Liab.
|
7,392.2 | 1,937.8 | 9,330.0 |
|
LT Debt
|
7,259.8 | 268.6 | 7,528.4 |
|
Total LT Debt
|
7,259.8 | 268.6 | 7,528.4 |
| Minority Interest (BS) | 5,312.1 | 23.8 | 5,335.9 |
| Deferred Taxes | 2,739.8 | 0.0 | 2,739.8 |
|
Other LT Liab.
|
4,119.8 | 850.9 | 4,970.7 |
|
Total Liabilities
|
26,823.7 | 3,081.2 | 29,904.9 |
| Shareholders Equity | |||
| Common Stock | 124.6 | 243.5 | 368.1 |
| Additional Paid in Capital | 0.0 | 419.2 | 419.2 |
| Retained Earnings | 29,786.2 | 3,638.4 | 33,424.6 |
| Treasure Stock | -2,714.1 | -3.8 | -2,717.8 |
| Other Equity | 0.0 | 0.0 | 0.0 |
|
Total Equity
|
27,196.8 | 4,297.3 | 31,494.1 |
|
Total Liab. & Equity
|
54,020.5 | 7,378.4 | 61,398.9 |
|
Shares Outstanding
|
1,725.1 | 190.8 | 1,915.9 |
| Cash Flow | |||
| Operating Cash Flow | |||
| CF Net Income | 0.0 | 758.1 | 758.1 |
| CF Depreciation | 0.0 | 430.5 | 430.5 |
| CF Deferred Taxes | 0.0 | 0.0 | 0.0 |
| Other Non-Cash Items | -411.2 | -86.6 | -497.8 |
| Change in Working Capital | 5,142.3 | 356.4 | 5,498.8 |
| Total Cash From Operating Activities | 4,731.1 | 1,458.4 | 6,189.5 |
| Investing Cash Flow (not calculated) | |||
| Capital Expenditures | -1,464.9 | -377.8 | -1,842.7 |
| Other Investing Cash Flows | -2,600.4 | -7.5 | -2,607.9 |
| Total Cash From Investing Activities | -4,065.3 | -385.3 | -4,450.6 |
| Financing Cash Flow (not calculated) | |||
| Dividends Paid | -1,393.2 | -291.2 | -1,684.4 |
| Purchase Or Sale of Stock | -1,575.5 | 74.0 | -1,501.4 |
| Purchase and Retirement of Debt | -735.2 | 0.0 | -735.2 |
| Other Financing Cash Flow | 1,221.1 | -579.8 | 641.3 |
| Total Cash From Financing Activities | -72.4 | -797.0 | -869.4 |
| Exchange Rate Effects | -68.5 | -12.6 | -81.1 |
| Net Change in Cash | 524.9 | 263.6 | 788.5 |
| Cash Taxes Paid | 603.6 | 252.3 | 855.8 |
| Cash Interest Paid | 151.1 | 15.1 | 166.1 |